1. Home
  2. DSY vs ALXO Comparison

DSY vs ALXO Comparison

Compare DSY & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DSY

Big Tree Cloud Holdings Limited Ordinary Shares

HOLD

Current Price

$0.42

Market Cap

39.9M

Sector

N/A

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.43

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSY
ALXO
Founded
2020
2015
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
79.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DSY
ALXO
Price
$0.42
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.30
AVG Volume (30 Days)
130.9K
303.0K
Earning Date
01-01-0001
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
120.37
N/A
EPS
0.01
N/A
Revenue
$7,323,356.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$33.50
N/A
Revenue Growth
16.37
N/A
52 Week Low
$0.40
$0.40
52 Week High
$7.33
$2.27

Technical Indicators

Market Signals
Indicator
DSY
ALXO
Relative Strength Index (RSI) 23.28 50.21
Support Level $0.40 $1.29
Resistance Level $0.48 $1.56
Average True Range (ATR) 0.02 0.14
MACD 0.01 0.00
Stochastic Oscillator 7.84 47.83

Price Performance

Historical Comparison
DSY
ALXO

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: